Onward Medical N.V. (ONWD.BR)
EUR 4.23
(0.95%)
EUR 4.23
(0.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -14.81 Million EUR | -18.18% |
| 2022 | -12.53 Million EUR | -373.53% |
| 2021 | -2.64 Million EUR | -75.48% |
| 2020 | -1.5 Million EUR | -431.34% |
| 2019 | -284 Thousand EUR | 49.91% |
| 2018 | -567 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -3.23 Million EUR | 9.57% |
| 2024 Q2 | -3.23 Million EUR | 0.0% |
| 2023 Q1 | -3.83 Million EUR | -2010.22% |
| 2023 FY | -194 Thousand EUR | 98.45% |
| 2023 Q4 | -3.57 Million EUR | 74.29% |
| 2023 Q3 | -13.92 Million EUR | -10411.11% |
| 2023 Q2 | 135 Thousand EUR | 103.52% |
| 2022 Q1 | -2.97 Million EUR | 9.03% |
| 2022 Q3 | -3.29 Million EUR | -2481.95% |
| 2022 Q4 | 200.5 Thousand EUR | 106.08% |
| 2022 Q2 | 138.5 Thousand EUR | 104.66% |
| 2022 FY | -12.53 Million EUR | -373.53% |
| 2021 Q1 | -2.02 Million EUR | -8.2% |
| 2021 FY | -2.64 Million EUR | -75.48% |
| 2021 Q4 | -3.26 Million EUR | 0.0% |
| 2021 Q3 | -3.26 Million EUR | -61.3% |
| 2021 Q2 | -2.02 Million EUR | 0.0% |
| 2020 Q2 | -1.79 Million EUR | 0.0% |
| 2020 Q3 | -1.87 Million EUR | -4.23% |
| 2020 Q1 | -1.79 Million EUR | 0.0% |
| 2020 FY | -1.5 Million EUR | -431.34% |
| 2020 Q4 | -1.87 Million EUR | 0.0% |
| 2019 FY | -284 Thousand EUR | 49.91% |
| 2018 FY | -567 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Nicox S.A. | -11.5 Million EUR | -28.819% |
| European Medical Solutions | 13.51 Million EUR | 209.674% |
| FERMENTALG | 535 Thousand EUR | 2869.72% |
| argenx SE | 925.49 Million EUR | 101.601% |
| BioSenic S.A. | 543 Thousand EUR | 2828.913% |
| Celyad Oncology SA | 33 Thousand EUR | 45003.03% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 843.129% |
| Oxurion NV | 104 Thousand EUR | 14348.077% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | 1217.496% |
| Financière de Tubize SA | -2.02 Million EUR | -630.1% |
| UCB SA | 3.34 Billion EUR | 100.443% |